SEC Comment Letter 0000000000-23-007197 to Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc.
Date: July 6, 2023 · CIK: 0001671584 · Accession: 0000000000-23-007197
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-273067
Letter
United States securities and exchange commission logo July 6, 2023 Marvin White President and Chief Executive Officer Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, Washington, 98121 Re:Aptevo Therapeutics Inc. Registration Statement on Form S-1 Filed June 30, 2023 File No. 333-273067 Dear Marvin White: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Sean Donahue, Esq.
Show Raw Text
United States securities and exchange commission logo
July 6, 2023
Marvin White
President and Chief Executive Officer
Aptevo Therapeutics Inc.
2401 4th Avenue, Suite 1050
Seattle, Washington, 98121
Re:Aptevo Therapeutics Inc.
Registration Statement on Form S-1
Filed June 30, 2023
File No. 333-273067
Dear Marvin White:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Sean Donahue, Esq.